USSTOCK.TODAY
Pre-Market
Log in Sign up

Gilead Sciences Signs 5-Year DevOps Extension Agreement with Cognizant

Pharmaceutical Technology +1 ·

GILD Gilead Sciences Inc
$144.23 -0.28%
View chart & analysis →
CTSH -1.63%
  1. 1Gilead Sciences has signed a 5-year DevOps extension agreement with Cognizant.
  2. 2This agreement follows more than 10 years of collaboration between the two companies.
  3. 3Gilead Sciences signed a contract with the Pan American Health Organization (PAHO) last month.

So what's the key point?

Gilead Sciences has decided to extend its technology cooperation agreement with Cognizant for another 5 years. This means the partnership between the two companies will continue after working together for over 10 years.

Source Pharmaceutical Technology +1 · View original ↗

Related 3-line summaries

Summit Therapeutics up 7.75% on positive Phase 3 ivosidenib data in cholangiocarcinoma InvestorsHub +1 · Aug 26Cognizant raises full-year profit outlook on financial services growth Reuters · Jul 30Cognizant posts 4.1% constant-currency revenue growth in Q2; guides 4–5.5% for the year MarketWatch +2 · Jul 29
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news